CN1507884A - Traditional Chinese medicine powder and decoction composition for treating cancer - Google Patents
Traditional Chinese medicine powder and decoction composition for treating cancer Download PDFInfo
- Publication number
- CN1507884A CN1507884A CNA021449015A CN02144901A CN1507884A CN 1507884 A CN1507884 A CN 1507884A CN A021449015 A CNA021449015 A CN A021449015A CN 02144901 A CN02144901 A CN 02144901A CN 1507884 A CN1507884 A CN 1507884A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- herba
- rhizoma
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种用于治疗癌症的中药散剂及汤剂组合物，该散剂组合物包括水蛭、蟾酥等二十九种天然药物制成的胶囊或片剂，而汤剂组合物含有核桃树枝和仙人掌等四味药物经沸煮后的浓缩提取液制成。所述散剂和汤剂配合服用对各类癌症，尤其是对于中晚期癌瘤具有奇特的治疗效果，而对于外科手术切除癌瘤的病患，可防止肿瘤复发、转移并能缓解放疗、化疗的毒副作用。The invention relates to a traditional Chinese medicine powder and decoction composition for treating cancer. The powder composition includes capsules or tablets made from 29 kinds of natural medicines such as leeches and toads. The decoction composition contains walnut branches and It is made from the boiled concentrated extract of the four herbs such as cactus. The combination of the powder and the decoction has a unique therapeutic effect on various types of cancer, especially for middle and advanced cancer, and for patients with surgically resected cancer, it can prevent tumor recurrence and metastasis and relieve the pain of radiotherapy and chemotherapy. toxic side effect.
Description
Technical field: the present invention relates to a kind of Chinese powder medicine compositions of cancer and Chinese medicine decoction compositions that is used with this Chinese powder medicine compositions of being used for the treatment of.
Background technology: with Chinese medicine composition or the now existing certain progress of its extract for treating cancer, as the fungus polysaccharide medicament that adopts fungi-medicines such as natural Lentinus Edodes, Tremella, Coriolous Dersicolor (Fr.) Quel to make slows down the cancerous cell growth, and adopt Radix Ginseng, the Radix Astragali, Cordyceps, Polyporus to wait the enhancing human body immunity function, increase with anticancer, with direct kill cancer cells of medicine such as Mylabris, Rhizoma Curcumae, Rabdosia rubescens and Venenum Bufoniss.Though above-mentioned various kinds of drug or its compositions can play certain therapeutical effect to cancer, but, cancerous cell invades and surrounding health tissue, or intrinsic propesties that remote part shift contiguous to body because having, particularly for the cancer sufferer in late period, may retain cancerous cell in multi-section positions such as skin, internal organs, bodies of gland, this patient's resistance is lower, as the medicine of simple employing human body immunity improving function, when improving body body constitution, also can promote the growth of cancerous cell; And only adopt the medicine of cancer inhibitting and killing cell, may in the cancer inhibitting and killing cell, also can press down and kill normal cell.The medicine that directly the cancer inhibitting and killing cell again can the human body immunity improving function in the prior art is also among exploring, yet, people never stop to seek a kind of ideal medicament that can solve above-mentioned contradiction, the Chinese medicine composition or its extract that are used for the treatment of cancer as many kinds such as CN1034985C, CN1060051C, but because the pathogeny of cancer is unclear as yet at present, simultaneously, the active ingredient of Chinese medicine or the property of medicine are difficult to that accurate quantitative analysis is arranged, can only be by animal experiment and clinical the checking.
Summary of the invention: task of the present invention provides a kind of directly kill cancer cell, can adjust the body equilibrium between yin and yang again simultaneously, and the Chinese powder medicine that is used for the treatment of cancer and the decoction compositions of a series of animals of process and clinical verification.
Main Ingredients and Appearance that the Chinese powder medicine compositions that is used for the treatment of cancer proposed by the invention is selected and content are (parts by weight):
Herba Agrimoniae, Rhizoma Paridis, each 20-30 part of Herba Hedyotidis Diffusae; fennel, Rhizoma Curcumae, Semen Coicis, Radix Et Rhizoma Rhei, the Rhizoma Atractylodis Macrocephalae, Indigo Naturalis, Radix Glycyrrhizae, each 10-15 part of Flos Carthami; Poria, Radix Astragali, Polyporus, Herba Scutellariae Barbatae, Radix Salviae Miltiorrhizae, Radix Trichosanthis, Herba Taraxaci, each 15-20 part of Rabdosia rubescens; Agkistrodon, Radix Ginseng, each 5-10 part of Scolopendra; Realgar, Mylabris, Hirudo, each 1-8 part of Venenum Bufonis, Calculus Bovis, Scorpio, each 4-15 part of Eupolyphaga Seu Steleophaga.
Available Main Ingredients and Appearance of described Chinese powder medicine compositions and content are (parts by weight):
Respectively 20 parts of Herba Agrimoniae, Rhizoma Paridis, Herba Hedyotidis Diffusaes; respectively 15 parts on fennel, Rhizoma Curcumae, Semen Coicis, Radix Et Rhizoma Rhei, the Rhizoma Atractylodis Macrocephalae, Indigo Naturalis, Radix Glycyrrhizae, Flos Carthami; respectively 15 parts of Poria, Radix Astragali, Polyporus, Herba Scutellariae Barbatae, Radix Salviae Miltiorrhizae, Radix Trichosanthis, Herba Taraxaci, Rabdosia rubescens; respectively 6 parts of Agkistrodon, Radix Ginseng, Scolopendras; respectively 2 parts of Realgar, Mylabris, Hirudo, Venenum Bufoniss, respectively 4 parts of Calculus Bovis, Scorpio, Eupolyphaga Seu Steleophagas.
Also available Main Ingredients and Appearance of medicament composition and content are (parts by weight) in described:
Respectively 30 parts of Herba Agrimoniae, Rhizoma Paridis, Herba Hedyotidis Diffusaes; respectively 10 parts on fennel, Rhizoma Curcumae, Semen Coicis, Radix Et Rhizoma Rhei, the Rhizoma Atractylodis Macrocephalae, Indigo Naturalis, Radix Glycyrrhizae, Flos Carthami; respectively 20 parts of Poria, Radix Astragali, Polyporus, Herba Scutellariae Barbatae, Radix Salviae Miltiorrhizae, Radix Trichosanthis, Herba Taraxaci, Rabdosia rubescens; respectively 10 parts of Agkistrodon, Radix Ginseng, Scolopendras; respectively 4 parts of Realgar, Mylabris, Hirudo, Venenum Bufoniss, respectively 15 parts of Calculus Bovis, Scorpio, Eupolyphaga Seu Steleophagas.
Be specifically designed to the Chinese medicine decoction compositions that is used with above-mentioned Chinese powder medicine compositions, said composition Main Ingredients and Appearance and content are (parts by weight): branch of Semen Juglandis 15-20 part, Radix et Caulis Opuntiae Dillenii 6-12 part, Fructus Jujubae 10-20 part, Ramulus Salicis Babylonicae 15-25 part.
After described powder composite is pressed the predetermined quantity compatibility and is concocted, through pulverize and fully mix after with the capsule of its metering of packing into or make tablet; And the medicine of respectively distinguishing the flavor of that the decoction compositions can be selected for use according to the above ratio puts into container and boils and boil, and the concentrated extracting solution that getting boils after boiling is also taken simultaneously by predetermined quantity and described match number of capsules or the tablet of Chinese powder medicine of making.
Because above-mentioned powder and Rhizoma Curcumae, Radix Salviae Miltiorrhizae, Radix Et Rhizoma Rhei, Hirudo, the Radix Astragali, Eupolyphaga Seu Steleophaga, Scorpio, Agkistrodon, Poria, Scolopendra, Radix Glycyrrhizae in the decoction compositions have effects such as blood circulation promoting and blood stasis dispelling, detumescence softening the hard mass, pain relieving; And Radix Et Rhizoma Rhei all has inhibitory action to melanin tumor, breast tumor and ehrlich carcinoma; Hirudo energy removing blood stasis collateral dredging eliminating mass suppresses and destruction is grown to carcinoma, helps anticarcinogen and immunologically competent cell and invades the cancerous tissue kill cancer cell; But Radix Glycyrrhizae invigorating the spleen and replenishing QI, eliminating fire and detoxication, lung moistening are removed expectorant, are relaxed the property of medicine, are suitable for deficiency of both QI and blood, shortness of breath and fatigue, Light-headedness, cough, gastral cavity abdomen contraction that various late periods, carcinoma occurred disease such as have a pain.In the compound mixture of treatment tumor, relax or lower the property and the toxicity thereof of high row as adjuvant; And Herba Agrimoniae, Radix Trichosanthis, Indigo Naturalis, Realgar, artificial Calculus Bovis, Venenum Bufonis, Rabdosia rubescens, Herba Portulacae Grandiflorae, Radix et Caulis Opuntiae Dillenii, Herba Hedyotidis Diffusae, Radix Sophorae Tonkinensis, branch of Semen Juglandis, Ramulus Salicis Babylonicae, Polyporus, Rhizoma Paridis, Semen Coicis etc. are as the heat-clearing and toxic substances removing principal agent.Because heat and toxic materials clearing away medicine can be controlled the infection of inflammation and other type around the tumor, with the diffusion of further control tumor.Herba Hedyotidis Diffusae in the compositions has stronger inhibitory action to acute lymphoblastic type, granulocyte type, monocyte type and chronic myelocytic leukemia, and the ascites hepatoma carcinoma cell is had inhibitory or killing effect; And Radix Ginseng, the Rhizoma Atractylodis Macrocephalae, fennel have the effect of invigorating the spleen and replenishing QI, stomach function regulating.
The inventor finds that powder in the above-mentioned composition and decoction cooperate and takes all kinds of cancers, especially has peculiar therapeutic effect for the middle and advanced stage carcinoma, and for the sufferer of surgical resection carcinoma, can prevent tumor recurrence, shift and can alleviate the toxic and side effects of radiotherapy, chemotherapy.To this, by zoopery and clinical the checking.
Kunming mouse is divided into groups to do in the acute toxicity test through Liaoning Research Institute of Traditional Chinese Medicine and institute of oncology with Chinese medicine composition proposed by the invention, its conclusion (of pressure testing) is: powder and priming decoction thereof, in the scope of possibility dosage, and increase once/day, mice does not see that the poisoning symptom and the acute toxicity phenomena of mortality take place.Viewing duration mice fur is smooth, and activity is not limited, and average weight has increase.Maximum tolerance is a mice 3.4-6.8kg body weight, sum total crude drug 88-176kg body weight.By the each 1g of adult, give " powder " and priming decoction 200g body weight 60kg for twice on the one and be meter, 183-366 times of behaving of mice tolerance multiple.What the mice maximum tolerated dose was equivalent to people's consumption then is safety more than 100 times.So the clinical practice of this medicine is safe.
Described in Table 1 powder promptly is meant powder proposed by the invention.In the animal experiment of table two, the cyclophosphamide of existing anticancer therapeutic certainly and TIANXIAN WAN and powder and decoction proposed by the invention find out obviously in the contrast test that respectively the effective percentage with powder and decoction inhibition carcinoma is higher than cyclophosphamide and TIANXIAN WAN respectively.And it can also be seen that in the table three, use simultaneously powder of the present invention and decoction compositions to its aggregative indicator in the test of mouse tumor far above TIANXIAN WAN.
Table four has been enumerated and has been used compositions proposed by the invention to patient with advanced cancer 209 routine patient's clinical observation statistics, its result shows: can control constant 109 examples in the recent period, tumor is obviously dwindled 72 examples with former foci disappearance, invalid 28 examples, and total effective rate is 86.6%.
Kunming mouse grouping experiment result to body weight 17% ±-2 grams is as follows:
Table one " powder " is to the effect (external) of tumor cell
Table two hepatic ascites and experimental result
| The tumor strain | Number of animals | The weight of animals | Heavy or the existence natural law of tumor | Suppression ratio or intercrescence rate elongation % | The P value | |||
| Beginning | The result | Beginning | Finish | Treatment | ||||
| Powder | Hepatic ascites | 9 | 9 | 18.1±1.62 | 31±8.96 | 17.7±5.32 | 48.99 | ＜0.01 |
| Decoction | 9 | 8 | 18.1±1.62 | 23.5±4.62 | 17±2.83 | 42.86 | ＜0.01 | |
| Cyclophosphamide | 9 | 9 | 17.9±1.27 | 20.8±6.75 | 15±5.36 | 26.26 | ||
| TIANXIAN WAN | 9 | 6 | 18.1±1.62 | 29.5±4.65 | 15.5±5.39 | 30.47 | ||
Table three " powder " is to the inhibitory action of mouse tumor
| The tumor strain | Group | Number of animals begins/finishes | Dosage g/Kg day * natural law | Before body weight (g) administration/administration after | Heavy (g) X ± SD of tumor | The P value | Suppression ratio % |
| ? ? ? ? S22 | The little TIANXIAN WAN size of the blank big powder of powder | 10????10 10????8 10????10 10????10 10????10 | 25×9 4.4×9 2.9×9 2.3×9 1.6×9 | 23????30 23????23 24????28 23????31 23????29 | 1.44±0.373 0.86±0.376 1.22±0.430 1.09±0.493 1.28±0.696 | ---- ＜0.005 ＞0.05 ＞0.05 ＞0.05 | ---- 40.28 15.28 24.30 11.11 |
| Blank big powder of powder and decoction TIANXIAN WAN | 11????11 10????9 10????10 10????9 | 30×10 59+0.42×10 30+0.20×10 2.8×10 | 20????30 20????27 20????30 19????27 | 1.30±0.644 0.87±0.345 0.64±0.244 0.81±0.550 | ---- ＞0.05 ＞0.05 ＞0.05 | ---- 33.08 50.76 37.69 | |
| ? S180 ? ? | Blank big (side of the closing) lower abdomen that looses is annotated auxilliary TIANXIAN WAN | 10????10 10????9 10????10 10????10 10????8 | 28×9 57±0.42×9 29+0.21×9 19×9 2.4×9 | 21????26 21????25 21????26 21????25 21????27 | 0.54±0.280 0.32±0.198 0.53±0.212 0.46±0.284 0.46±0.197 | ---- ＜0.05 ＞0.05 ＞0.05 ＞0.05 | ---- 40.74 1.85 14.81 14.81 |
Table 4:
| Tumor type | Total case | The treatment situation | Effective percentage % | ||
| Age | Sex | Number | |||
| Pulmonary carcinoma | ? 90 ? | ? 35-75 ? | The men and women | 65 ? 25 | 88.9 ? |
| Gastric cancer | ? 68 ? | ? 23-71 ? | The men and women | 41 ? 27 | 88.23 ? |
| Esophageal carcinoma | ? 12 ? | ? 48--71 ? | The men and women | 7 ? 5 | ? 75 ? |
| Hepatocarcinoma | ? 15 ? | ? 34--75 ? | The men and women | 8 ? 7 | ? 74.4 ? |
| Laryngeal carcinoma | ? 9 ? | ? 40--63 ? | The men and women | 5 ? 4 | 66.7 ? |
| Thyroid carcinoma | ? 5 ? | ? 28--50 ? | The men and women | 2 ? 3 | 100 ? |
| Breast carcinoma | 3 | 37--74 | The woman | 3 | 100 |
| Left renal carcinoma | 1 | ?53 | The man | 1 | 100 |
| Nasopharyngeal carcinoma | 1 | 13 | The man | 1 | 100 |
| Pericardium cancer | 1 | 63 | The man | 1 | 100 |
| The melanin malignant tumor | 1 | 34 | The woman | 1 | 100 |
| Cerebroma | 1 | 32 | The man | 1 | 100 |
| Carcinoma of descending colon | 1 | 50 | The man | 1 | 100 |
| Carcinoma of head of pancreas | 1 | 67 | The man | 1 | 100 |
Claims (4)
1, a kind of Chinese powder medicine compositions that is used for the treatment of cancer is characterized in that: Main Ingredients and Appearance that this powder composite is selected and content are (parts by weight):
Herba Agrimoniae, Rhizoma Paridis, each 20-30 part of Herba Hedyotidis Diffusae; fennel, Rhizoma Curcumae, Semen Coicis, Radix Et Rhizoma Rhei, the Rhizoma Atractylodis Macrocephalae, Indigo Naturalis, Radix Glycyrrhizae, each 10-15 part of Flos Carthami; Poria, Radix Astragali, Polyporus, Herba Scutellariae Barbatae, Radix Salviae Miltiorrhizae, Radix Trichosanthis, Herba Taraxaci, each 15-20 part of Rabdosia rubescens; Agkistrodon, Radix Ginseng, each 5-10 part of Scolopendra; Realgar, Mylabris, Hirudo, each 1-8 part of Venenum Bufonis, Calculus Bovis, Scorpio, each 4-15 part of Eupolyphaga Seu Steleophaga.
2, Chinese powder medicine compositions according to claim 1 is characterized in that Main Ingredients and Appearance and content that this powder composite is selected are (parts by weight):
Respectively 20 parts of Herba Agrimoniae, Rhizoma Paridis, Herba Hedyotidis Diffusaes; respectively 15 parts on fennel, Rhizoma Curcumae, Semen Coicis, Radix Et Rhizoma Rhei, the Rhizoma Atractylodis Macrocephalae, Indigo Naturalis, Radix Glycyrrhizae, Flos Carthami; respectively 15 parts of Poria, Radix Astragali, Polyporus, Herba Scutellariae Barbatae, Radix Salviae Miltiorrhizae, Radix Trichosanthis, Herba Taraxaci, Rabdosia rubescens; respectively 6 parts of Agkistrodon, Radix Ginseng, Scolopendras; respectively 2 parts of Realgar, Mylabris, Hirudo, Venenum Bufoniss, respectively 4 parts of Calculus Bovis, Scorpio, Eupolyphaga Seu Steleophagas.
3, Chinese powder medicine compositions according to claim 1 and 2 is characterized in that Main Ingredients and Appearance and content that this powder composite is selected are (parts by weight):
Respectively 30 parts of Herba Agrimoniae, Rhizoma Paridis, Herba Hedyotidis Diffusaes; respectively 10 parts on fennel, Rhizoma Curcumae, Semen Coicis, Radix Et Rhizoma Rhei, the Rhizoma Atractylodis Macrocephalae, Indigo Naturalis, Radix Glycyrrhizae, Flos Carthami; respectively 20 parts of Poria, Radix Astragali, Polyporus, Herba Scutellariae Barbatae, Radix Salviae Miltiorrhizae, Radix Trichosanthis, Herba Taraxaci, Rabdosia rubescens; respectively 10 parts of Agkistrodon, Radix Ginseng, Scolopendras; respectively 4 parts of Realgar, Mylabris, Hirudo, Venenum Bufoniss, respectively 15 parts of Calculus Bovis, Scorpio, Eupolyphaga Seu Steleophagas.
4, be specifically designed to the Chinese medicine decoction compositions that is used with the described Chinese powder medicine compositions of claim 1, this decoction compositions Main Ingredients and Appearance and content are (parts by weight):
Branch of Semen Juglandis 15-20 part, Radix et Caulis Opuntiae Dillenii 6-12 part, Fructus Jujubae 10-20 part, Ramulus Salicis Babylonicae 15-25 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021449015A CN1305515C (en) | 2002-12-16 | 2002-12-16 | Chinese medicinal powder and decoction composition for treating cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021449015A CN1305515C (en) | 2002-12-16 | 2002-12-16 | Chinese medicinal powder and decoction composition for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1507884A true CN1507884A (en) | 2004-06-30 |
| CN1305515C CN1305515C (en) | 2007-03-21 |
Family
ID=34232159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021449015A Expired - Fee Related CN1305515C (en) | 2002-12-16 | 2002-12-16 | Chinese medicinal powder and decoction composition for treating cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1305515C (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011559B (en) * | 2007-02-01 | 2011-06-01 | 南中兴 | Traditional Chinese medicine preparation for treating malignant tumor and its preparation method |
| CN101590209B (en) * | 2009-06-08 | 2011-06-22 | 郭凯 | Medicament for treating tumors and preparation method thereof |
| CN101554416B (en) * | 2008-04-08 | 2012-09-19 | 南京中科集团股份有限公司 | Chinese medicine composition and preparation method and application thereof |
| CN102716414A (en) * | 2012-05-28 | 2012-10-10 | 大连圣弘医药有限公司 | Anti-tumor medicinal composition containing algal polysaccharide sulfate and preparation method for composition |
| CN102772523A (en) * | 2012-08-09 | 2012-11-14 | 谢瑜 | Bitter glossy ganoderma composition for oncotherapy and preparation method of bitter glossy ganoderma composition |
| CN103908613A (en) * | 2014-04-03 | 2014-07-09 | 荆振海 | Traditional Chinese medicine medicament for treating melanoma and preparation method thereof |
| CN104096171A (en) * | 2014-07-14 | 2014-10-15 | 王素玲 | Traditional Chinese medicine composition for treating liver cancer, and preparation method of traditional Chinese medicine composition |
| CN104127808A (en) * | 2014-07-15 | 2014-11-05 | 南中兴 | Traditional Chinese medicinal preparation for treating malignant tumors, and preparation method thereof |
| CN105288050A (en) * | 2015-11-26 | 2016-02-03 | 杨修芳 | Medicine for treating cancer |
| CN107823296A (en) * | 2017-12-01 | 2018-03-23 | 贵州健瑞安药业有限公司 | A kind of pedicure prescription for the treatment of cancer and preparation method thereof |
| CN108371704A (en) * | 2018-01-20 | 2018-08-07 | 江西永昇制药股份有限公司 | The interim medicine composition of compound dandelion carcinosis radiotherapy and chemotherapy |
| CN109498780A (en) * | 2019-01-30 | 2019-03-22 | 钱兴媄 | A kind of Chinese medicine composition and preparation method thereof with antitumor action |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1144691A (en) * | 1996-09-25 | 1997-03-12 | 周森 | Aifukang soluble granules and its preparation method |
-
2002
- 2002-12-16 CN CNB021449015A patent/CN1305515C/en not_active Expired - Fee Related
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011559B (en) * | 2007-02-01 | 2011-06-01 | 南中兴 | Traditional Chinese medicine preparation for treating malignant tumor and its preparation method |
| CN101554416B (en) * | 2008-04-08 | 2012-09-19 | 南京中科集团股份有限公司 | Chinese medicine composition and preparation method and application thereof |
| CN101590209B (en) * | 2009-06-08 | 2011-06-22 | 郭凯 | Medicament for treating tumors and preparation method thereof |
| CN102716414A (en) * | 2012-05-28 | 2012-10-10 | 大连圣弘医药有限公司 | Anti-tumor medicinal composition containing algal polysaccharide sulfate and preparation method for composition |
| CN102772523B (en) * | 2012-08-09 | 2014-11-19 | 谢瑜 | Bitter ganoderma composition for tumor treatment and preparation method thereof |
| CN102772523A (en) * | 2012-08-09 | 2012-11-14 | 谢瑜 | Bitter glossy ganoderma composition for oncotherapy and preparation method of bitter glossy ganoderma composition |
| CN103908613A (en) * | 2014-04-03 | 2014-07-09 | 荆振海 | Traditional Chinese medicine medicament for treating melanoma and preparation method thereof |
| CN104096171A (en) * | 2014-07-14 | 2014-10-15 | 王素玲 | Traditional Chinese medicine composition for treating liver cancer, and preparation method of traditional Chinese medicine composition |
| CN104127808A (en) * | 2014-07-15 | 2014-11-05 | 南中兴 | Traditional Chinese medicinal preparation for treating malignant tumors, and preparation method thereof |
| CN105288050A (en) * | 2015-11-26 | 2016-02-03 | 杨修芳 | Medicine for treating cancer |
| CN107823296A (en) * | 2017-12-01 | 2018-03-23 | 贵州健瑞安药业有限公司 | A kind of pedicure prescription for the treatment of cancer and preparation method thereof |
| CN108371704A (en) * | 2018-01-20 | 2018-08-07 | 江西永昇制药股份有限公司 | The interim medicine composition of compound dandelion carcinosis radiotherapy and chemotherapy |
| CN109498780A (en) * | 2019-01-30 | 2019-03-22 | 钱兴媄 | A kind of Chinese medicine composition and preparation method thereof with antitumor action |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1305515C (en) | 2007-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041312A (en) | Traditional Chinese medicine composition with antineoplastic effect and preparation method and application thereof | |
| CN102961648B (en) | Traditional Chinese medicine compound preparation for treating advanced colorectal cancer | |
| CN113730535A (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application of traditional Chinese medicine preparation of traditional Chinese medicine composition | |
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN1507884A (en) | Traditional Chinese medicine powder and decoction composition for treating cancer | |
| CN103055285B (en) | Traditional Chinese medicine for treating forepart hepetocirrhosis and preparation method thereof | |
| CN105878930A (en) | Traditional Chinese medicine preparation for inhibiting hepatic metastasis of colonic carcinoma | |
| CN102727779B (en) | Pharmaceutical composition for treating ovarian cysts and preparation method thereof | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN103520659B (en) | Traditional Chinese medicine for treating cancer | |
| CN102631538A (en) | Traditional Chinese medicine for treating heart disease | |
| CN1323711C (en) | Chinese medicine for treating liver cancer and carcinoma of pancreas | |
| CN101214365A (en) | Chinese medicine composing prescription for treating mastoproliferation | |
| CN100584370C (en) | Traditional Chinese Medicine for Prevention and Treatment of Gastrointestinal Cancer | |
| CN105012552A (en) | Traditional Chinese medicine for treating wind-prevailing migratory arthralgia type rheumatic arthritis and preparation method | |
| CN104940752A (en) | Chinese medicine preparation for treating vulva ulcer and preparing method thereof | |
| CN112691168B (en) | Traditional Chinese medicine composition for preventing and treating nuclear radiation injury and preparation method thereof | |
| CN102861292A (en) | Medicament for treating esophageal cancer and preparation method thereof | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN1253003A (en) | Compound graceful jassamine preparation | |
| CN114848784A (en) | A Chinese medicinal composition for treating cancer | |
| CN121177365A (en) | A traditional Chinese medicine preparation for treating chemotherapy-induced peripheral neuropathy, its preparation method and application | |
| CN104547695B (en) | It is a kind of for treating the pharmaceutical composition and its application of trigeminal neuralgia | |
| CN104758749A (en) | Traditional Chinese medicine composition for treating liver cancer | |
| CN104288405B (en) | A kind of preparation method for non-small cell lung cancer postoperative chemotherapy ancillary drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Hui Document name: Notification of registration procedures and notice of patent for invention |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Hui Document name: Deemed a waiver of a patent claim |
|
| AD01 | Patent right deemed abandoned | ||
| C20 | Patent right or utility model deemed to be abandoned or is abandoned | ||
| CI01 | Correction of invention patent gazette |
Correction item: deemed abandonment of patent right Correct: The revocation of the patent right is deemed to be abandoned False: deemed abandonment of patent right Number: 27 Page: 1082 Volume: 22 |
|
| ERR | Gazette correction |
Free format text: CORRECT: PATENT RIGHT DEEMED TO BE ABANDONED; FROM: PATENT RIGHT DEEMED TO BE ABANDONED TO: REVOCATION DEEMED TO ABANDON PATENT RIGHT |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070321 Termination date: 20121216 |